Fact CheckerSign in

NCT07367932Not yet recruitingPhase 4

Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis

Crisaborole 2% Versus Tacrolimus 0.03% Ointments for the Treatment of Mild to Moderate Atopic Dermatitis: A Comparative Study

Source: ClinicalTrials.gov · Last updated 26 Jan 2026

Brief summary (registry, in English)

This study will compare the efficacy and safety of crisaborole ointment with tacrolimus ointment, in the treatment of patients with mild-to-moderate atopic dermatitis.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
30 (estimated)
First submitted
28 Dec 2025
Start date
Feb 2026
Primary completion date
Apr 2026
Lead sponsor
Cairo University
NCT number
NCT07367932

What you commit to

  • Study type: Interventional · Phase 4
  • Planned participants: 30
  • From Feb 2026 to the primary completion date, Apr 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients receiving topical treatment for AD and/or pruritus within the past 14 days and/or systemic treatment within the past month.

Other illness

  • Clinically infected eczema.

Other

  • Baseline Investigator's Static Global Assessment (ISGA) score of severe (4).
  • Associated comorbidities that exacerbate pruritus.
  • Pregnancy and lactation if in the childbearing period

Who the study is looking for

  • Patients with diagnosis of AD, according to Hanifin and Rajka criteria.
  • Patients of both genders
  • Age 5-25 years
  • Baseline Investigator's Static Global Assessment (ISGA) score of mild (2) or moderate (3).

Age in the registry: 5 years to 25 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.